Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Simon

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|July 24, 2013
[Understand the neurodevelopment of language: a necessity to prevent learning disabilities in children], A Charollais, S Marret, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Haplotype editing with CRISPR/Cas9 as a therapeutic approach for dominant-negative missense mutations in <i>NEFL</i>Poorvi H Dua, Bazilco M J Simon, Chiara B E Marley, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 21, 2025
Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFLPoorvi H Dua, Bazilco M J Simon, Chiara B E Marley, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|July 24, 2013
[Understand the neurodevelopment of language: a necessity to prevent learning disabilities in children], A Charollais, S Marret, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Haplotype editing with CRISPR/Cas9 as a therapeutic approach for dominant-negative missense mutations in <i>NEFL</i>Poorvi H Dua, Bazilco M J Simon, Chiara B E Marley, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 21, 2025
Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFLPoorvi H Dua, Bazilco M J Simon, Chiara B E Marley, et al.
Pageof 4